Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12051510 | 0.87 | SORD (0.31) | — | |
| SCHEMBL2625488 | 0.84 | NFKB1 (0.31) | — | |
| SCHEMBL21153211 | 0.84 | — | — | |
| SCHEMBL21400714 | 0.84 | ADORA2A (0.37) | POLBHRH4 | |
| SCHEMBL14572429 | 0.81 | EGFR (0.32) | HRH4 | |
| SCHEMBL19050223 | 0.81 | ALDH1A1 (0.33) | — | |
| SCHEMBL13333647 | 0.81 | — | — | |
| SCHEMBL19367730 | 0.81 | CYP1A2 (0.36) | — | |
| SCHEMBL15215098 | 0.81 | POLB (0.31) | POLB | |
| SCHEMBL16922209 | 0.79 | F2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0668898-B1 | METHOD OF SEALING OFF WATER-INFLUX POINTS IN ROCK FORMATIONS | BERGWERKSVERBAND GMBH (DE) | 1997-03-12 | — | — | EP | claimed |
| EP-0656917-B1 | PROCESS FOR USING A SYNTHETIC RESIN SYSTEM | BERGWERKSVERBAND GMBH (DE) | 1997-03-12 | — | — | EP | claimed |
| WO-2025088285-A1 | ECOBIOLOGICAL TOPICAL COMPOSITION FOR TREATING SKIN REDNESS AND DISCOMFORT | NAOS INSTITUTE OF LIFE SCIENCE (FR) | 2025-05-01 | — | — | WO | disclosed |
| US-20240238304-A1 | Small Molecule Degraders of DOT1L and Uses Thereof | NORTHWESTERN UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-20240238304-A1 | Small Molecule Degraders of DOT1L and Uses Thereof | NORTHWESTERN UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20230295457-A1 | SURFACE TREATMENT LIQUID AND SURFACE TREATMENT METHOD | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230272143-A1 | SURFACE TREATMENT LIQUID AND HYDROPHILIZING TREATMENT METHOD | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-08-31 | — | — | US | disclosed |
| US-20230159556-A1 | NOVEL PROTEIN KINASE INHIBITORS | TENOVA PHARMACEUTICALS INC. | 2023-05-25 | — | — | US | disclosed |
| US-20220153751-A1 | BIFUNCTIONAL COMPOUNDS | BIOTHERYX, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20090251049-A1 | Organic electroluminescent device utilizing organic electroluminescent compounds | GRACEL DISPLAY INC. (KR) | 2009-10-08 | — | — | US | disclosed |
| US-20090189519-A1 | Organic electroluminescent compounds and light emitting diode using the same | GRACEL DISPLAY INC. (KR) | 2009-07-30 | — | — | US | disclosed |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-12 | — | — | US | disclosed |
| US-20090005399-A1 | Substituted Imidazo[2,1-b]thiazole Compounds and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-01-01 | — | — | US | disclosed |
| US-20080242702-A1 | Paclitaxel enhancer compound | SYNTA PHARMACEUTICALS CORP. | 2008-10-02 | — | — | US | disclosed |
| US-20080214655-A1 | Paclitaxel enhancer compounds | SYNTA PHARMACEUTICALS CORP. | 2008-09-04 | — | — | US | disclosed |
| US-7368473-B2 | Paclitaxel enhancer compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-05-06 | — | — | US | disclosed |
| US-7345094-B2 | Paclitaxel enhancer compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-18 | — | — | US | disclosed |
| US-5429949-A | S-triazine degrading bacteria | OHIO STATE RESEARCH FOUNDATION (US) | 1995-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090189519-A1 | Organic electroluminescent compounds and light emitting diode using the same | OCIAD1, AOX1, OCIAD2 | POLB 899/4885HRH4 2734/4885 |
| US-20090005399-A1 | Substituted Imidazo[2,1-b]thiazole Compounds and Uses Thereof | GRM5, GRIK5, GRM1 | POLB 4542/4885HRH4 209/4885 |
| US-20090251049-A1 | Organic electroluminescent device utilizing organic electroluminescent compounds | OCIAD2, OCIAD1, LAGE3 | POLB 907/4885HRH4 4480/4885 |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | HRH4, HRH3, HRH2 | POLB 4593/4885HRH4 1/4885 |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | POLB 4692/4885HRH4 1751/4885 |
| US-20230159556-A1 | NOVEL PROTEIN KINASE INHIBITORS | ERBB2, ALK, ERBB3 | POLB 3016/4885HRH4 4393/4885 |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | POLB 4699/4885HRH4 1063/4885 |
| US-20080242702-A1 | Paclitaxel enhancer compound | CENPE, FOXM1, C9 | POLB 2310/4885HRH4 73/4885 |
| US-20240238304-A1 | Small Molecule Degraders of DOT1L and Uses Thereof | DOT1L, STUB1, BAZ2B | POLB 3306/4885HRH4 4567/4885 |
| US-20080214655-A1 | Paclitaxel enhancer compounds | ABCC8, FOXM1, C9 | POLB 1858/4885HRH4 93/4885 |
| US-20220153751-A1 | BIFUNCTIONAL COMPOUNDS | CDK2, CDK6, CDK5 | POLB 230/4885HRH4 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.